Boosting endocannabinoids in tissue reduced heightened pain in a depression mouse model

Repeated IFN-alpha treatment increased formalin-evoked pain behavior in mice. Endocannabinoid levels (2-AG and AEA) rose in pain-processing brain regions (PAG and RVM) after formalin in IFN-alpha-treated mice. Local administration of endocannabinoid-boosting drugs (PF3845 and MJN110) reduced the heightened pain response in depressed but not control mice.

Male C57/Bl6 mice received repeated IFN-alpha (8000 IU/g/day) to induce depressive-like behavior confirmed by forced swim and sucrose preference tests. Pain responses were measured via hot plate and formalin tests, with endocannabinoid levels measured in brain and peripheral tissues by LC-MS/MS.

Depression and chronic pain frequently co-occur, and this study reveals the endocannabinoid system as a mechanistic link. The finding that boosting endocannabinoids specifically helped the heightened pain in depression suggests targeted therapeutic potential for this common comorbidity.

Many patients with depression also experience amplified pain, and current treatments address each condition separately. Understanding that the endocannabinoid system mediates the pain-depression overlap could lead to single treatments that address both simultaneously.

Mouse model with pharmacologically induced depression (IFN-alpha), which may not fully represent human depression. Only male mice used. Only inflammatory pain was studied, not other pain types. Peripheral drug administration only.